Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mou… [+4328 chars]Read More
Eli Lilly stock tumbles 10 after drug giant misses estimates and slashes profit guidance CNBC
